Comparative Pharmacology
Head-to-head clinical analysis: PHERAZINE VC W CODEINE versus QOLIANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHERAZINE VC W CODEINE versus QOLIANA.
PHERAZINE VC W/ CODEINE vs QOLIANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codeine: Opioid receptor agonist (mu-receptor), suppresses cough reflex. Phenylephrine: Alpha-1 adrenergic receptor agonist, vasoconstrictor. Promethazine: Histamine H1 receptor antagonist, anticholinergic, antiemetic.
QOLIANA (elagolix) is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to GnRH receptors in the pituitary gland, thereby reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to decreased ovarian production of estrogen and progesterone, resulting in a hypoestrogenic state.
Adults: 5 mL (one teaspoonful) orally every 4 to 6 hours as needed; each 5 mL contains promethazine hydrochloride 5 mg, phenylephrine hydrochloride 5 mg, and codeine phosphate 10 mg. Maximum daily dose: codeine 120 mg (6 doses).
Initiate at 5 mg orally once daily, increase as tolerated to 10 mg once daily. Maximum dose 20 mg once daily.
None Documented
None Documented
Codeine: 2.5-3.5 hours (terminal); phenylephrine: 2-3 hours; promethazine: 10-19 hours (clinical context: prolonged in renal impairment, accumulation with chronic use).
Terminal elimination half-life is 12 hours (range 10–15 hours) in healthy adults; may extend to 18–24 hours in patients with moderate hepatic impairment (Child-Pugh B).
Renal: codeine (40-70% as free and conjugated metabolites, including morphine, norcodeine, and hydromorphone); phenylephrine (80-90% as conjugated metabolites, 10% unchanged); promethazine (primarily as sulfoxides and glucuronides, renal elimination about 70%). Fecal/biliary: minor.
Renal excretion of unchanged drug accounts for approximately 30% of elimination; biliary/fecal excretion accounts for 60% (including metabolites); 10% is metabolized with negligible pulmonary elimination.
Category D/X
Category C
Opioid Agonist
Opioid Agonist